Stocks and Investing Stocks and Investing
Fri, April 28, 2023

Vikram Purohit Maintained (ASND) at Hold with Increased Target to $109 on, Apr 28th, 2023


Published on 2024-10-28 03:09:32 - WOPRAI, Vikram Purohit
  Print publication without navigation


Vikram Purohit of Morgan Stanley, Maintained "Ascendis Pharma A/S" (ASND) at Hold with Increased Target from $107 to $109 on, Apr 28th, 2023.

Vikram has made no other calls on ASND in the last 4 months.



There are 5 other peers that have a rating on ASND. Out of the 5 peers that are also analyzing ASND, 1 agrees with Vikram's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Leland Gershell of "Oppenheimer" Downgraded from Buy to Hold on, Wednesday, April 5th, 2023


These are the ratings of the 4 analyists that currently disagree with Vikram


  • David Lebowitz of "Citigroup" Maintained at Strong Buy with Decreased Target to $146 on, Wednesday, April 5th, 2023
  • Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy with Decreased Target to $92 on, Tuesday, April 4th, 2023
  • Joseph Schwartz of "SVB Leerink" Maintained at Buy with Increased Target to $163 on, Tuesday, January 17th, 2023
  • Derek Archila of "Wells Fargo" Maintained at Buy with Increased Target to $177 on, Tuesday, January 3rd, 2023

Contributing Sources